Development and validation of models predicting treatment patterns in women with urinary urgency and/or urgency incontinence: A Symptoms of Lower Urinary Tract Dysfunction Research Network observational cohort study.
暂无分享,去创建一个
J. Jelovsek | C. Amundsen | Anna C. Kirby | Qian Liu | Qian Liu | Abigail R. Smith | J. Geynisman-Tan | C. Bretschneider | H. H. Lai | Sarah A. Mansfield | Z. Kirkali | Ziya Kirkali | Cindy L Amundsen | Julia Geynisman-Tan | Anna Kirby | John Eric Jelovsek
[1] R. Dmochowski,et al. Associations Between Unmet Social Needs and Overactive Bladder , 2022, The Journal of urology.
[2] William T. Berg,et al. A retrospective longitudinal evaluation of new overactive bladder patients in an FPMRS urologist practice: Are patients following up and utilizing third‐line therapies? , 2020, Neurourology and urodynamics.
[3] T. Soda,et al. Overactive bladder medication: Persistence, drug switching, and reinitiation , 2020, Neurourology and urodynamics.
[4] E. Illiano,et al. Italian real-life clinical setting: the persistence and adherence with mirabegron in women with overactive bladder , 2020, International Urology and Nephrology.
[5] J. Nazir,et al. Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review , 2018, BMJ Open.
[6] R. Bödeker,et al. Anticholinergic burden and comorbidities in patients attending treatment with trospium chloride for overactive bladder in a real-life setting: results of a prospective non-interventional study , 2018, BMC Urology.
[7] K. Weinfurt,et al. Baseline Lower Urinary Tract Symptoms in Patients Enrolled in LURN: A Prospective, Observational Cohort Study , 2017, The Journal of urology.
[8] V. Dandolu,et al. Comparing anticholinergic persistence and adherence profiles in overactive bladder patients based on gender, obesity, and major anticholinergic agents , 2017, Neurourology and urodynamics.
[9] Tomomi Kimura,et al. Persistence and adherence to overactive bladder medications in Japan: A large nationwide real‐world analysis , 2017, International journal of urology : official journal of the Japanese Urological Association.
[10] H. Bogner,et al. Is self‐reported adherence associated with clinical outcomes in women treated with anticholinergic medication for overactive bladder? , 2016, Neurourology and urodynamics.
[11] K. Weinfurt,et al. Symptoms of Lower Urinary Tract Dysfunction Research Network. , 2016, The Journal of urology.
[12] S. Mathew,et al. Medication Adherence: Truth and Consequences☆ , 2016, The American journal of the medical sciences.
[13] Tae Heon Kim,et al. Persistence and compliance with medication management in the treatment of overactive bladder , 2016, Investigative and clinical urology.
[14] R. Dmochowski,et al. The Burden of Overactive Bladder on US Public Health , 2016, Current Bladder Dysfunction Reports.
[15] C. Thompson,et al. Moving towards a comprehensive assessment of lower urinary tract symptoms (LUTS) , 2012, Neurourology and urodynamics.
[16] K. Giannitsas,et al. An Overview of the Clinical Use of Antimuscarinics in the Treatment of Overactive Bladder , 2011, Advances in urology.
[17] Daniel J Buysse,et al. The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008. , 2010, Journal of clinical epidemiology.
[18] K. Coyne,et al. Assessing patients’ descriptions of lower urinary tract symptoms (LUTS) and perspectives on treatment outcomes: results of qualitative research , 2010, International journal of clinical practice.
[19] R. Freeman,et al. An international urogynecological association (IUGA)/international continence society (ICS) joint report on the terminology for female pelvic floor dysfunction , 2010, Neurourology and urodynamics.
[20] T. Kamarck,et al. A global measure of perceived stress. , 1983, Journal of health and social behavior.